Company news

Liquidia Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

October 1, 2024

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

September 29, 2024

Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

September 15, 2024

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

September 10, 2024

Liquidia to Present at Upcoming Investor Conferences

August 27, 2024

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

August 21, 2024

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

August 18, 2024

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

August 15, 2024

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 6, 2024

Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

July 30, 2024

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

June 17, 2024

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

June 2, 2024

Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

May 28, 2024

Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

May 9, 2024

Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024

May 6, 2024

Liquidia Corporation to Present at BofA Securities Health Care Conference 2024

May 6, 2024

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

March 31, 2024

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

March 12, 2024

Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024

March 5, 2024

Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

January 29, 2024

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

January 24, 2024

Liquidia Corporation Announces Updates to Operations Leadership

January 18, 2024

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

January 7, 2024

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

January 4, 2024

Liquidia Corporation Announces $100 Million in New Financings

January 3, 2024

Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

December 19, 2023

Liquidia Announces Pricing of Public Offering of Common Stock

December 11, 2023

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

October 30, 2023

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

September 24, 2023

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

September 5, 2023

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023

Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder

July 26, 2023

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

July 23, 2023

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

June 27, 2023

Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference

May 30, 2023

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

May 18, 2023

Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023

Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference

May 1, 2023

Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023

April 26, 2023

Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications

April 2, 2023

Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023

March 8, 2023

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)

February 1, 2023

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.